Jacob Berlin

Jacob is the CEO and co-founder of Terray Therapeutics, a chemistry-first, AI-native biotech working at the intersection of computation and experimentation on small molecule solutions to some of the most challenging diseases. Terray was formed around a new experimental technology that increases the scale while reducing the cost and cycle time for small molecule evaluation, creating massive amounts of highly precise data to solve the most pressing problems for patients in need. Jacob and his team developed this breakthrough technology in his lab at the City of Hope, where he was an associate professor. Under Jacob’s visionary and mission driven leadership, Terray has built a world class team of computation and drug development leaders, built an internal pipeline focused on new treatments for immunology disorders, established partnerships with global pharma partners, and scaled from that initial invention to a highly automated lab that supports the company’s AI and computational drug discovery and development platform.

Jacob’s academic work centered on the intersection of nanotechnology and chemistry, and he has been recognized by the industry as an expert in the field, with numerous awards, and more than fifteen thousand citations of his work. Jacob holds 20 patents, a BA in Chemistry from Harvard and was awarded his PhD in organometallic chemistry from Caltech, where he studied with Nobel Laureate Bob Grubbs. Jacob completed his postdoctoral training at MIT and Rice University, focusing on synthetic chemistry and nanotechnology, before founding his lab at City of Hope. Jacob lives with his family in the Los Angeles area.